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Outcome of allogeneic bone marrow transplantation with lymphocyte- 
depleted marrow grafts in adult patients with myelodysplastic 
syndromes
V Mattijssen, A Schattenberg, N Schaap, F Preijers and T De Witte
Summary : MDS are mostly seen in the elderly. While the overall inci­
dence is about 2-4 per 100000 per year, this is 20-30 per 
100 000 per year in the population over 70 years.1 The clini-Thirty-five patients with myelodysplastic syndromes
(MDS) were treated with BMT between 1986 and 1994. cal course of MDS varies from an indolent form to a rapidly
Their median age was 41 years (range 23-60). Thirteen fatal disease. Patients die from infection or bleeding, com-
patients had transfusion-dependent refractory anaemia plications of transfusion, or acute leukaemia. Conventional
(RA). Twenty-two patients suffered from more treatment is not curative.2 In cases with excess of blasts or
advanced stages of MDS, 15 being in complete remission following progression to AML, intensive chemotherapy
(CR) after chemotherapy. In 31 recipients, pretrans- may result in CR in 50-60% of patients, but the median
plant conditioning consisted of cyclophosphamide and remission duration is usually less than 12 months, while a
TBI with or without the addition of idarubucin; four median survival following chemotherapy of 7-15 months
patients were conditioned with other schedules. Donors has been recorded.3,4 An increasing incidence of MDS is
were genotypically HLA-identical and MLC-negative being observed in relatively young patients surviving after
siblings in 32, and others in three cases. All patients chemotherapy, immunotherapy and/or radiotherapy for
received a graft depleted of 98% of T lymphocytes using other diseases. These treatment-related MDS have an even
counterflow centrifugation. Fourteen patients are alive 
and in continuous remission with a median follow-up of
worse clinical course,4,5 
Allogeneic BMT offers a potentially curative treatment
20 months (range 15—113) after BMT. Seven patients for younger MDS patients. In a recent review, the prob-
relapsed between 3 and 18 months after BMT and sub- ability of 5-year disease-free survival (DFS) following
sequently died. Fourteen transplantation-related deaths BMT in a group of 93 patients was 40%, while the actual
occurred. Outcome in patients under and over 40 years DFS varied from 35 to 63% in six smaller studies with
old was comparable. The probability of disease-free sur- shorter follow-up.6 Median age in these patient groups
vival (DFS) at 2 years after BMT was 39% (95% confi- ranged from 23 to 36 years, and a younger age was found to
dence interval (Cl), 22-56%). Considering patients with be a favourable prognostic factor. We report a retrospective
HLA-identical and MLC-negative sibling donors trans- study of our results of BMT in a group of 35 adults with
MDS. This patient group is relatively old as compared to 
the previously published series.6
planted for RA (n = 11) or more advanced stages of 
MDS in CR {n = 14), the probabilities of DFS were 73%
(95% Cl, 47-99%) and 42% (95% Cl, 15-69%), 
respectively. This indicates that BMT with lymphocyte- 
depleted grafts can cure a substantial number of rela­
tively old patients with MDS, especially when grafts
from HLA-identical and MLC-negative siblings are Between April 1986 and December 1994, 35 patients with
Patients and methods
used and patients are suffering from RA.
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Myelodysplastic syndromes (MDS) encompass a group of 
clonal haematopoietic disorders. They are characterized by 
refractory cytopenia and dysplastic changes in blood and 
bone marrow, and show a tendency to progress to AML.
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MDS were treated with allogeneic BMT. Patient character­
istics and transplantation data are summarized in Table 1.
median age was 41 years (range 23-60). Thirteen 
patients had refractory anaemia (RA) and were transfusion- 
dependent, seven patients had RA with excess of blasts 
(RAEB), 11 patients had RAEB in transformation (RAEB- 
t), and one patient suffered from chronic myelomonocytic 
leukaemia (CMMoL), as defined by the French-American- 
British (FAB) classification.7 Three patients had secondary 
AML (sAML) which had evolved from MDS. Five out of 
the total group of 35 patients had developed MDS after 
previous radiotherapy (for malignant melanoma, n -  1) or 
immunosuppressive treatment for rheumatoid 
(n = 2), paroxysmal nocturnal haemoglobinuria (n = 1), and 
severe aplastic anaemia (n = 1). In the others, the MDS was
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Patient and transplantation characteristics
No patients
Median age, years (range)
Sex, male/female
Stage o f disease at transplantation 
RA, not pretreated 
RAEB, not pretreated 
RAEB in CR 
RAEB-t in CR 
RAEB-t in PR 
CMMoL in CR 
sAML in CR 
sAML in PR 
Disease aetiology 
Idiopathic
Previous radio- or immunosuppressive therapy 
Median duration of disease before BMT, mo (range)
Marrow donors 
Median age, years (range)
Genotypically HLA-identical and MLC-neg sibling 
Two-locus mismatched family member 
Matched unrelated donor 
Pretransplant conditioning regimen
Cyclophosphamide (2 X 60 mg/kg i.v.), TBI (2 X 4, 5 Gy)
Cyclophosphamide (2 X 60 mg/kg i.v.), TBI ( 2 X 6  Gy)
Cyclophosphamide (2 X 60 mg/kg i.v.), idarubicin (42 mg/m- i.v.), TBI (2 X 4, 5 Gy) 
Other
Total
35
41 (23-60) 
21/14
13
3
4 
9 
2 
1  
1  
2
30
5
9 (4-69)
40 (19—65)
3 ?
1
2
2
7
22
4
^ 4 0  years
17
30
9/8
8
1
2
4
0
0
1
1
1 5
2
12
33
14
1
2
2
3
9
3
> 40 years
18
50
12/6
5
2
2
5
2
1
0
1
1 5
3
6
47
18
0
0
0
4
1 3
1
without apparent cause. The median duration of MDS 
before BMT was 9 months (range, 4-69). Prior to BMT, 
19 patients received remission-induction and consolidation 
chemotherapy with schedules as used for the treatment of 
AML. This resulted in CR in 15 patients (four RAEB, nine 
RAEB-t, one CMMoL, and one sAML), and PR in four 
patients (two RAEB-t and two sAML). None of the 13 
patients transplanted for RA were pretreated.
Donors were genotypically HLA-identical and MLC- 
negative siblings in 32 cases. One patient received a graft 
from a two-locus mismatched family member, and two 
from HLA-identical unrelated donors. Conditioning regi­
mens consisted of cyclophosphamide (2 X  60 mg/kg i.v.) 
and TBI (2 X  4, 5-6 Gy) with or without the addition of 
idarubicin (42 mg/m2 i.v.) in 31 patients, and other sched­
ules in four patients. All patients received grafts depleted 
of approximately 98% of T lymphocytes using counterflow
prophylaxis post-transplant consisted of cyclosporin A. All 
patients were cared for in single rooms with filtered air 
under positive pressure, and all received oral selective gut 
decontamination, acyclovir for herpes virus prophylaxis, 
and cotrimoxazole for Pneumocystis carinii prophylaxis.
Acute GVHD was graded 1 to 4 according to the criteria 
described by Glucksberg et al.9 Chronic GVHD was classi­
fied as limited or extensive, as described by Shulman et 
al..10 Patients were considered evaluable for acute and 
chronic GVHD if they survived more than 14 days and 
more than 100 days after BMT, respectively.
Statistical analyses were performed using the Kaplan- 
Meier product-limit method. Actuarial curves were calcu­
lated for relapse and for DFS. 95% confidence intervals 
(Cl) were calculated as: relapse or DFS estimate at 24
months after transplantation ± 2  X  s.e. Differences betweei 
subgroups were evaluated by the log rank test. P value: 
<0.05 were considered significant.
Results
Fourteen out of 35 patients are alive in continuous CR wit! 
a median follow-up after BMT of 20 months (range 15- 
113). Relapse of disease was observed in seven patients 
including one patient transplanted for RA, two for RAEE 
in CR, one for RAEB-t in PR, one for CMMoL in CR, anc 
two transplanted for sAML in PR. These relapses occurred 
between 3 and 18 months after BMT (median 6 months). 
Twenty-one patients have died. Eighteen of them died 
within 6 months (median 2 months) after BMT. Principal 
causes of death were relapse (n = 4), and transplantation- 
related causes encompassing graft failure (n = 2, including 
the patient with the two-locus mismatched family donor), 
infectious complications (n = 9, including the two patients 
with matched unrelated donors), acute GVHD (n = 2), and 
heart failure (n=  I). Three patients died beyond 6 months. 
All three had undergone retransplantation for relapse. One 
died of a cerebrovascular accident at 36 months after first 
BMT, and 10 days after retransplantation which was per­
formed 24 months after relapse of RA. The other two 
patients were free of disease for 53 and 81 months, respect­
ively, after retransplantation for relapsed RAEB. They ulti­
mately relapsed again and died. Remarkably, both late 
relapses after second BMT presented primarily as an extra- 
medullary myeloblastic infiltration in soft tissues (stomach 
and pleural cavity), followed by overt AML at a later stage. 
Figures 1 and 2 represent probabilities of relapse and DFS,
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Although there was a tendency towards better outcome in 
patients with RA (group B), the differences between groups 
A, B and C were not statistically significant.
According to age two separate groups were analyzed, 
encompassing patients =s40 years and patients >40 years. 
With regard to disease and transplantation characteristics, 
these two groups were largely comparable (Table 1). On 
the one hand, the younger group included all three patients 
without genotypically HLA-idenlical sibling. On the other 
hand the older group included less patients with RA (five 
vs eight, Table 1). The probability of DFS for patients «40  
years (n = 17) was 33% (95% Cl, 9-57%), and for patients 
84 96 108 120 >40 years (n = 18) 44% (95% Cl, 21-67%), which was not
c
B
Figure 1 Probability ol' relapse of disease following BMT for patients 
with MDS. A, total group (n = 35); B, subgroup of patients with RA trans­
planted with marrow from HLA-identical and MLC-negative siblings 
(« = 11); C, subgroup of patients with RAEB, RAEB-t, CMMoL, or 
sAML, transplanted in CR with marrow from HLA-identical and MLC- 
negative siblings (n = 14). Log rank P, B vs C -  0.3. Bars represent 
relapse-free patients.
not S
-one patients were evaluable for acute GVHD. 
Four of them (actual rate 13%) developed grade 2-4 acute 
GVHD. In two patients (6%), GVHD was the principal 
cause of death. Limited chronic GVHD occurred in four 
(17%), and severe chronic GVHD in three (13%) out of 23 
evaluable patients.
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Figure  2 Probability of DFS following BMT for patients with MDS. A, 
total group (n ~ 35); B, subgroup of patients with RA transplanted with 
marrow from HLA-identical and MLC-negative siblings (// = II);  C* sub­
group of patients with RAEB, RAEB-t, CMMoL, or sA M L  transplanted 
in CR with marrow from HLA-identical and MLC-negative siblings 
(n = 14). Log rank B v\v C = 0.2. Bars represent patients alive in 
continuous CR.
respectively, after BMT. Besides the total group (group A,
n = 35), two mon
Discussion
For patients with MDS and AML evolving from MDS, allo­
geneic BMT offers the only curative treatment option. Use 
of BMT, however, is limited to a minority of relatively 
young patients, especially those with HLA-identical sibling 
donors. Outcome of BMT in MDS and sAML has been 
described by several authors, mostly in retrospective
ses of heterogeneous patient groups/1,11 17 The 
of MDS in itself, and the variety of preparative
and interpretation of 
the actuarial DFS 
MDS patients following BMT of 39% fits within the range 
of overall actuarial DFS of 35-56%, as described by
6.M i7 Qur patient group, with a median age of 41
years, and 26% of the patients being 50-60 years of age, 
is one of the oldest BMT groups of MDS patients reported 
to date. Only Anderson et aV8 published a series with the
same median age. Although a 
has been described in
6,15,14
30-35
the 18 patients over 40 years old in our study 
did not fare worse than the 17 patients who were 40 years 
old or younger.
Besides a hi edian age, use of T cell
row grafts effected by counter ce n tri fu ga t i o n e 1 u tri at ion
; were ani is specific for our MDS study group as compared to those 
encompassing patients with RA with HLA-identical and published by others. T lymphocyte depletion of the marrow
MLC-negative donors (group B, n = 11)» and graft is performed in order to reduce the incidence and
patients with RAEB, RAEB-t, CMMoL or sAML, trans- severity of GVHD. GVHD is a serious problem following 
planted in CR with HLA-identical and MLC-negative sib- allogeneic BMT, often resulting in death. In the previously
reported MDS patient groups, the incidence of fetal GVHD 
was 20-35% in the studies without T cell-depletion11,13,17,19
ling donors (group C, n = 14). The probability of relapse 
(Figure 1) at 2 years after BMT for the total group (A) is 
34% (95% Cl, 12-56%)), and for the subgroups B and C and 9 
11 % (95% Cl, 0-32%) and 34% (95% Cl, 2-66%), respect- receiving T cell-depleted marrow.12,13 In comparison to 
ively. Figure 2 represents continuous DFS following (first) this, the percentage of patients who died of GVHD in
in groups, with of the patients
BMT. The median DFS for the total group is 6 months. 
Probabilities of DFS at 2 years after BMT are 39% (95%
present study is low (two out of 35, 
depletion implies an increased risk of gn
Cl, 22-56%) for group A, 73% (95% Cl, 47-99%) for ease relapse. In two of our 35 patients
group B, and Cl, 15-69%) for group C. resulting in death occurred. The overall >e rate of 20%,
793
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however, is identical to previously reported series. 
That the overall relapse rate is not
(», 17.1K
could be
explained by the intensive pretreatment our patients 
received, with remission-induction chemotherapy in cases 
with excess of blasts, and intensive conditioning with two 
cytotoxic agents besides TBI in most patients.
Since the present MDS population is quite hetero­
geneous, we distinguished two more homogeneous patient 
groups. The first subgroup consisted of 11 patients with 
RA, with HLA-identical and MLC-negative sibling donors. 
With their probability of relapse of 11% and probability 
of DFS of 73%, they appear to constitute a favourable 
subgroup, as was found by others before.6,12,17’10
The second subgroup 14 patients with
more advanced MDS (RAEB, RAEB-t, CMMoL or
sAML), in first CR after previous chemo-
therapy with marrow from HLA-identical and MLC-nega­
tive siblings. With a probability of DFS of 42%, their 
results were clearly better than for the seven patients not 
in CR before BMT (four in PR and three non-pretreated), 
and who all died (three of relapse, one of GVHD, one of 
graft failure and two of infectious complications). These 
groups are rather small, but improved outcome of MDS 
patients being in CR before BMT as compared to failures 
to chemotherapy has been described before.12,14 Otherwise, 
in other series, comparable6,12,13 or even better14 results 
were obtained while no attempt was made to get MDS 
patients with excess of blasts into CR before BMT.
The experience with BMT in MDS patients with marrow 
from donors other than genotypically matched siblings is 
limited. In the present study the three patients in this cate­
gory all died due to treatment-related causes. Both worse1(1 
and comparable6-18 results as compared to procedures with 
genotypically HLA-matched 
described before.
donors have been
Our indicate that BMT with T
depleted grafts from HLA-identical and MLC-negative sib­
lings can cure patients with MDS up to 60 years old. A
4 De Witte T, Suciu S, Peetermans M et al. Intensive chemo­
therapy for poor prognosis myelodysplasia (MDS) and sec­
ondary acute myeloid leukemia (sAML) following MDS of 
more than 6 months duration. A pilot study by the Leukemia 
Cooperative Group of the European Organisation for Research 
and Treatment in Cancer (EORTC-LCG). Leukemia 1995; 9: 
1805-1811.
5 Kantarjian HM, Keating MJ, Walters RS et al. Therapy- 
related leukemia and myelodysplastic syndrome: clinical, 
cytogenetic, and prognostic features. J Clin Oncol 1986; 4: 
1748-1757.
6 Anderson JE, Appelbauin FR, Storb R. An update on allo­
geneic marrow transplantation for myelodysplastic syndrome.
Leuk Lymphoma 1995; 17: 95-99.
7 Bennett JM, Catovsky D, Daniel MT et al. Proposals for the 
classification of the myelodysplastic syndromes. Br J Haema­
tol 1982; 51: 189-199.
8 De Witte T, Raymakers R, Plas A et al. Bone marrow repopu­
lation capacity after transplantation of lymphocyte depleted
marrow using counterfiow centrifugation. 
Transplantation 1984; 37: 151-155.
9 Glucksberg H, Storb R, Feier A et al. Clinical manifestations 
of graft-versus-host disease in human recipients of marrow 
from HLA-matched sibling donors. Transplantation 1974; 18: 
295-304.
10 Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft- 
versus-host syndrome in man. Am J Med 1980; 69: 204-217.
11 O’Donnell MR, Nademanee AP, Snyder DS et al. Bone mar­
row transplantation for myelodysplastic and myeloprolifer­
ative syndromes. J Clin Oncol 1987; 5: 1822-1826.
12 De Witte T, Zwaan F, Hermans J et al. Allogeneic bone mar­
row transplantation for secondary leukaemia and myelodyspl­
astic syndrome: a survey by die Leukaemia Working Party of 
the European Bone Marrow Transplantation Group (EBMTG). 
B r J  Haematol 1990; 74: 151-155.
13 Longmore G, Guinan EC, Weinstein HJ et al. Bone marrow 
transplantation for myelodysplasia and secondary acute non- 
lymphoblastic leukemia. J Clin Oncol 1990; 8: 1707-1714.
14 Sutton L, Leblond V, Le Maignan C et al. Bone marrow trans­
plantation for myelodysplastic syndrome and secondary leuke­
mia: outcome of 86 patients. Bone Marrow Transplant 1991 ;
7 (Suppl): 39.
good probability o f  DFS was seen especially in patients 15 Nevill TJ, Shepherd JD, Reece DE et al. Treatment of myelod-
I 4  A MHl  _ t  * » _ m A j * .  *
with RA. Future studies will give us more information on 
favourable subgroups of MDS patients for BMT, on the 
criteria to be used for pretreatment with chemotherapy, and 
on the timing of BMT within the course of MDS.
ome with busulfan-cyclophosphamide con­
ditioning followed by allogeneic BMT. Bone Marrow Trans­
plant 1992; 10: 445-450.
16 Ratanatharathorn V, Karanes C, Uberti J et al. Busu I fan-based
and marrow transplantation in 
patients with myelodysplastic syndromes. Blood 1993; 81: 
2194-2199.
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